FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079481807> ?p ?o ?g. }

• W2079481807 endingPage "2068" @default.
• W2079481807 startingPage "2062" @default.
• W2079481807 abstract "Abstract Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR) is associated with superior overall survival (OS) for patients with chronic lymphocytic leukemia (CLL). Alemtuzumab (A) was added to FCR (CFAR) in a phase 2 trial for high-risk untreated patients < 70 years with serum β-2 microglobulin (β2M) ≥ 4 mg/L. Sixty patients were enrolled; median age was 59 years (range, 42-69); 75% were male; median β2M was 5.1 mg/L (range, 4-11.6); and 51% were Rai III-IV. Complete remission (CR) was achieved in 70%, partial remission (PR) in 18%, nodular PR in 3%, for an overall response of 92%. Of 14 patients with 17p deletion, CR was achieved by 8 (57%). Of 57 BM samples evaluated by 3-color flow cytometry at the end of treatment, 41 (72%) were negative for residual disease. Grade 3-4 neutropenia and thrombocytopenia occurred with 33% and 13% courses, respectively. The median progression-free survival was 38 months and median OS was not reached. In conclusion, CFAR is an active frontline regimen for high-risk CLL. Response rates and survival are comparable with historic high-risk FCR-treated patients. CFAR may be a useful frontline regimen to achieve CR in patients with 17p deletion before allogeneic stem cell transplantation." @default.
• W2079481807 created "2016-06-24" @default.
• W2079481807 creator A5006104041 @default.
• W2079481807 creator A5009747339 @default.
• W2079481807 creator A5027575595 @default.
• W2079481807 creator A5028026524 @default.
• W2079481807 creator A5028845635 @default.
• W2079481807 creator A5035354255 @default.
• W2079481807 creator A5046097970 @default.
• W2079481807 creator A5046135731 @default.
• W2079481807 creator A5058755419 @default.
• W2079481807 creator A5084290698 @default.
• W2079481807 creator A5085393928 @default.
• W2079481807 creator A5089428686 @default.
• W2079481807 date "2011-08-25" @default.
• W2079481807 modified "2023-10-12" @default.
• W2079481807 title "Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia" @default.
• W2079481807 cites W1841628176 @default.
• W2079481807 cites W2001850157 @default.
• W2079481807 cites W2008542227 @default.
• W2079481807 cites W2019274594 @default.
• W2079481807 cites W2024303920 @default.
• W2079481807 cites W2054577656 @default.
• W2079481807 cites W2073873436 @default.
• W2079481807 cites W2088934767 @default.
• W2079481807 cites W2097852595 @default.
• W2079481807 cites W2125134816 @default.
• W2079481807 cites W2140606816 @default.
• W2079481807 cites W2143749371 @default.
• W2079481807 cites W2152025286 @default.
• W2079481807 cites W2153334574 @default.
• W2079481807 cites W2158644739 @default.
• W2079481807 cites W2160992697 @default.
• W2079481807 cites W2162125647 @default.
• W2079481807 cites W60865865 @default.
• W2079481807 doi "https://doi.org/10.1182/blood-2011-01-329177" @default.
• W2079481807 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4081295" @default.
• W2079481807 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21750315" @default.
• W2079481807 hasPublicationYear "2011" @default.
• W2079481807 type Work @default.
• W2079481807 sameAs 2079481807 @default.
• W2079481807 citedByCount "83" @default.
• W2079481807 countsByYear W20794818072012 @default.
• W2079481807 countsByYear W20794818072013 @default.
• W2079481807 countsByYear W20794818072014 @default.
• W2079481807 countsByYear W20794818072015 @default.
• W2079481807 countsByYear W20794818072016 @default.
• W2079481807 countsByYear W20794818072017 @default.
• W2079481807 countsByYear W20794818072019 @default.
• W2079481807 countsByYear W20794818072021 @default.
• W2079481807 countsByYear W20794818072022 @default.
• W2079481807 countsByYear W20794818072023 @default.
• W2079481807 crossrefType "journal-article" @default.
• W2079481807 hasAuthorship W2079481807A5006104041 @default.
• W2079481807 hasAuthorship W2079481807A5009747339 @default.
• W2079481807 hasAuthorship W2079481807A5027575595 @default.
• W2079481807 hasAuthorship W2079481807A5028026524 @default.
• W2079481807 hasAuthorship W2079481807A5028845635 @default.
• W2079481807 hasAuthorship W2079481807A5035354255 @default.
• W2079481807 hasAuthorship W2079481807A5046097970 @default.
• W2079481807 hasAuthorship W2079481807A5046135731 @default.
• W2079481807 hasAuthorship W2079481807A5058755419 @default.
• W2079481807 hasAuthorship W2079481807A5084290698 @default.
• W2079481807 hasAuthorship W2079481807A5085393928 @default.
• W2079481807 hasAuthorship W2079481807A5089428686 @default.
• W2079481807 hasBestOaLocation W20794818071 @default.
• W2079481807 hasConcept C126322002 @default.
• W2079481807 hasConcept C141071460 @default.
• W2079481807 hasConcept C143998085 @default.
• W2079481807 hasConcept C2776694085 @default.
• W2079481807 hasConcept C2776755627 @default.
• W2079481807 hasConcept C2777063308 @default.
• W2079481807 hasConcept C2777938653 @default.
• W2079481807 hasConcept C2778461978 @default.
• W2079481807 hasConcept C2778714382 @default.
• W2079481807 hasConcept C2779015954 @default.
• W2079481807 hasConcept C2779263901 @default.
• W2079481807 hasConcept C2779338263 @default.
• W2079481807 hasConcept C2780653079 @default.
• W2079481807 hasConcept C2780790343 @default.
• W2079481807 hasConcept C2781413609 @default.
• W2079481807 hasConcept C2911091166 @default.
• W2079481807 hasConcept C71924100 @default.
• W2079481807 hasConcept C90924648 @default.
• W2079481807 hasConceptScore W2079481807C126322002 @default.
• W2079481807 hasConceptScore W2079481807C141071460 @default.
• W2079481807 hasConceptScore W2079481807C143998085 @default.
• W2079481807 hasConceptScore W2079481807C2776694085 @default.
• W2079481807 hasConceptScore W2079481807C2776755627 @default.
• W2079481807 hasConceptScore W2079481807C2777063308 @default.
• W2079481807 hasConceptScore W2079481807C2777938653 @default.
• W2079481807 hasConceptScore W2079481807C2778461978 @default.
• W2079481807 hasConceptScore W2079481807C2778714382 @default.
• W2079481807 hasConceptScore W2079481807C2779015954 @default.
• W2079481807 hasConceptScore W2079481807C2779263901 @default.
• W2079481807 hasConceptScore W2079481807C2779338263 @default.
• W2079481807 hasConceptScore W2079481807C2780653079 @default.
• W2079481807 hasConceptScore W2079481807C2780790343 @default.

• next